RTRX vs. KMDA, NLTX, ERAS, VRCA, CTNM, RENB, CRMD, AKBA, EPIX, and TERN
Should you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Kamada (KMDA), Neoleukin Therapeutics (NLTX), Erasca (ERAS), Verrica Pharmaceuticals (VRCA), Contineum Therapeutics (CTNM), Renovaro (RENB), CorMedix (CRMD), Akebia Therapeutics (AKBA), ESSA Pharma (EPIX), and Terns Pharmaceuticals (TERN). These companies are all part of the "medical" sector.
Travere Therapeutics (NASDAQ:RTRX) and Kamada (NASDAQ:KMDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings, media sentiment and community ranking.
Kamada has a net margin of 5.81% compared to Travere Therapeutics' net margin of -49.13%. Kamada's return on equity of 5.66% beat Travere Therapeutics' return on equity.
Travere Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Kamada has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Kamada has a consensus price target of $11.00, suggesting a potential upside of 113.59%. Given Kamada's higher possible upside, analysts clearly believe Kamada is more favorable than Travere Therapeutics.
Travere Therapeutics received 112 more outperform votes than Kamada when rated by MarketBeat users. Likewise, 73.17% of users gave Travere Therapeutics an outperform vote while only 64.98% of users gave Kamada an outperform vote.
20.4% of Kamada shares are held by institutional investors. 4.6% of Travere Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Kamada has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kamada had 2 more articles in the media than Travere Therapeutics. MarketBeat recorded 2 mentions for Kamada and 0 mentions for Travere Therapeutics. Kamada's average media sentiment score of 0.29 beat Travere Therapeutics' score of 0.00 indicating that Kamada is being referred to more favorably in the news media.
Summary
Kamada beats Travere Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Travere Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Travere Therapeutics Competitors List
Related Companies and Tools
